<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38740499</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.</ArticleTitle><Pagination><StartPage>e085272</StartPage><MedlinePgn>e085272</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e085272</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-085272</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-viral fatigue syndromes. There remains no clear pharmacological therapy for patients with this subtype of PCC, which can be referred to as post-COVID fatigue syndrome (PCFS). A low dose of the opioid antagonist naltrexone (ie, low-dose naltrexone (LDN)) has emerged as an off-label treatment for treating fatigue and other symptoms in PCC. However, only small, non-controlled studies have assessed LDN in PCC, so randomised trials are urgently required.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">A prospective, randomised, double-blind, parallel arm, placebo-controlled phase II trial will be performed to assess the efficacy of LDN for improving fatigue in PCFS. The trial will be decentralised and open to eligible individuals throughout the Canadian province of British Columbia (BC). Participants will be recruited through the province-wide Post-COVID-19 Interdisciplinary Clinical Care Network (PC-ICCN) and research volunteer platform (REACH BC). Eligible participants will be 19-69 years old, have had a confirmed or physician-suspected SARS-CoV-2 infection at least 3 months prior and meet clinical criteria for PCFS adapted from the Institute of Medicine ME/CFS criteria. Individuals who are taking opioid medications, have a history of ME/CFS prior to COVID-19 or history of significant liver disease will be excluded. Participants will be randomised to an LDN intervention arm (n=80) or placebo arm (n=80). Participants in each arm will be prescribed identical capsules starting at 1&#x2009;mg daily and follow a prespecified schedule for up-titration to 4.5&#x2009;mg daily or the maximum tolerated dose. The trial will be conducted over 16 weeks, with assessments at baseline, 6, 12 and 16 weeks. The primary outcome will be fatigue severity at 16 weeks evaluated by the Fatigue Severity Scale. Secondary outcomes will include pain Visual Analogue Scale score, overall symptom severity as measured by the Patient Phenotyping Questionnaire Short Form, 7-day step count and health-related quality of life measured by the EuroQol 5-Dimension questionnaire.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">The trial has been authorised by Health Canada and approved by The University of British Columbia/Children's and Women's Health Centre of British Columbia Research Ethics Board. On completion, findings will be disseminated to patients, caregivers and clinicians through engagement activities within existing PCC and ME/CFS networks. Results will be published in academic journals and presented at conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT05430152.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Naik</LastName><ForeName>Hiten</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5193-4618</Identifier><AffiliationInfo><Affiliation>Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada hiten.naik@ubc.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Post-COVID-19 Interdisciplinary Clinical Care Network, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cooke</LastName><ForeName>Erin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2921-1701</Identifier><AffiliationInfo><Affiliation>BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulter</LastName><ForeName>Travis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Women's Health Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Complex Chronic Diseases Program, BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyer</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bone</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0001-7704-1677</Identifier><AffiliationInfo><Affiliation>BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Melody</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Women's Health Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Complex Chronic Diseases Program, BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristobal</LastName><ForeName>Jaymie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Women's Health Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Complex Chronic Diseases Program, BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>R Jane</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fraser Health Authority, Surrey, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacul</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Women's Health Research Institute, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Complex Chronic Diseases Program, BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Practice, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05430152</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="Y">Naltrexone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009292" MajorTopicYN="Y">Narcotic Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="N">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic Disease</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">PAIN MANAGEMENT</Keyword><Keyword MajorTopicYN="N">Post-Acute COVID-19 Syndrome</Keyword></KeywordList><CoiStatement>Competing interests: HN is a member of the Canadian Guidelines for Post-COVID-19 Condition Guideline Team for Pharmacologic and Nonpharmacologic Clinical Interventions. The other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>14</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>14</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>13</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38740499</ArticleId><ArticleId IdType="pmc">PMC11097836</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-085272</ArticleId><ArticleId IdType="pii">bmjopen-2024-085272</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Statistics Canada . Long-term symptoms in Canadian adults who tested positive for COVID-19 or suspected an infection, January 2020 to August 2022, 2022. Available: https://www150.statcan.gc.ca/n1/daily-quotidien/221017/dq221017b-eng.pdf [Accessed 24 Feb 2023].</Citation></Reference><Reference><Citation>
National Center for Health Statistics . Long COVID household pulse survey. Available: www.cdc.gov/nchs/covid19/pulse/long-covid.htm [Accessed 1 Oct 2023].</Citation></Reference><Reference><Citation>
Adjaye-Gbewonyo D, Vahratian A, Perrine CG, et al. . Key findings Data from the National Health Interview Survey What percentage of adults ever had Long COVID or currently have Long COVID, and did it differ by sex?, Available: https://www.cdc.gov/nchs/products/index.htm
</Citation></Reference><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, et al. . Recovery and symptom Trajectories up to two years after SARS-Cov-2 infection: population based, longitudinal cohort study. BMJ 2023;381:e074425. 10.1136/bmj-2022-074425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074425</ArticleId><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21:133&#x2013;46. 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022;28:1706&#x2013;14. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID: let patients help define long-lasting COVID symptoms. Nature 2020;586:170. 10.1038/d41586-020-02796-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02796-2</ArticleId><ArticleId IdType="pubmed">33029005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, et al. . Long Covid in adults discharged from UK hospitals after COVID-19: A prospective, Multicentre cohort study using the ISARIC WHO clinical Characterisation protocol. Lancet Reg Health Eur 2021;8:100186. 10.1016/j.lanepe.2021.100186</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention . Post-COVID Conditions: Information for Healthcare Providers, 2022. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html [Accessed 30 Apr 2023].</Citation></Reference><Reference><Citation>Callard F, Perego E. How and why patients made long Covid. Soc Sci Med 2021;268:113426. 10.1016/j.socscimed.2020.113426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Macpherson K, Cooper K, Harbour J, et al. . Experiences of living with long COVID and of Accessing Healthcare services: A qualitative systematic review. BMJ Open 2022;12:e050979. 10.1136/bmjopen-2021-050979</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-050979</ArticleId><ArticleId IdType="pmc">PMC8753091</ArticleId><ArticleId IdType="pubmed">35017239</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker S, Goodfellow H, Pookarnjanamorakot P, et al. . Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: A cross-sectional observational study. BMJ Open 2023;13:e069217. 10.1136/bmjopen-2022-069217</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069217</ArticleId><ArticleId IdType="pmc">PMC10335413</ArticleId><ArticleId IdType="pubmed">37286327</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804. 10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. . Development of a definition of Postacute sequelae of SARS-Cov-2 infection. JAMA 2023;329:1934. 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik H, Shao S, Tran KC, et al. . Evaluating fatigue in patients recovering from COVID-19: validation of the fatigue severity scale and single item screening questions. Health Qual Life Outcomes 2022;20:170. 10.1186/s12955-022-02082-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-02082-x</ArticleId><ArticleId IdType="pmc">PMC9792925</ArticleId><ArticleId IdType="pubmed">36575437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite LC, Carvalho L, Queiroz DM de, et al. . Can the post-COVID-19 functional status scale discriminate between patients with different levels of fatigue, quality of life and functional performance Pulmonology 2022;28:220&#x2013;3. 10.1016/j.pulmoe.2022.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2022.01.001</ArticleId><ArticleId IdType="pmc">PMC8752288</ArticleId><ArticleId IdType="pubmed">35120866</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, et al. . Symptoms, complications and management of long COVID: a review. J R Soc Med 2021;114:428&#x2013;42. 10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Magel T, Meagher E, Boulter T, et al. . Fatigue presentation, severity, and related outcomes in a prospective cohort following post-COVID-19 hospitalization in British Columbia. Front Med (Lausanne) 2023;10:1179783. 10.3389/fmed.2023.1179783</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1179783</ArticleId><ArticleId IdType="pmc">PMC10344448</ArticleId><ArticleId IdType="pubmed">37457578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, et al. . Therapeutic trials for long COVID-19: A call to action from the interventions Taskforce of the RECOVER initiative. Front Immunol 2023;14. 10.3389/fimmu.2023.1129459</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamoulle M, Louazon E, Antonacci T, et al. . Long COVID needs novel clinical trials. Nature 2024;626:954. 10.1038/d41586-024-00560-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-024-00560-4</ArticleId><ArticleId IdType="pubmed">38413755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Tran KC, Binka M, et al. . Use of latent class analysis and patient reported outcome measures to identify distinct long COVID phenotypes: A longitudinal cohort study. PLoS ONE 2023;18:e0286588. 10.1371/journal.pone.0286588</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0286588</ArticleId><ArticleId IdType="pmc">PMC10237387</ArticleId><ArticleId IdType="pubmed">37267379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, et al. . Data-driven identification of post-acute SARS-Cov-2 infection Subphenotypes. Nat Med 2023;29:226&#x2013;35. 10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Quach TC, Tiwari A, et al. . Myalgic Encephalomyelitis/ chronic fatigue syndrome is common in post-acute sequelae of SARS-Cov-2 infection (PASC): results from a post-COVID-19 Multidisciplinary clinic. Front Neurol 2023;14. 10.3389/fneur.2023.1090747</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2023.1090747</ArticleId><ArticleId IdType="pmc">PMC9998690</ArticleId><ArticleId IdType="pubmed">36908615</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;cary S, Gaboury I, Poirier S, et al. . Humility and acceptance: working within our limits with long COVID and Myalgic Encephalomyelitis/ chronic fatigue syndrome. J Orthop Sports Phys Ther 2021;51:197&#x2013;200. 10.2519/jospt.2021.0106</Citation><ArticleIdList><ArticleId IdType="doi">10.2519/jospt.2021.0106</ArticleId><ArticleId IdType="pubmed">33930983</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS)-A systemic review and comparison of clinical presentation and Symptomatology. Medicina 2021;57:418. 10.3390/medicina57050418</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to Myalgic Encephalomyelitis/chronic fatigue syndrome. Front Med (Lausanne) 2020;7:606824. 10.3389/fmed.2020.606824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, O&#x2019;Brien KK. Conceptualising long COVID as an episodic health condition. BMJ Glob Health 2021;6:e007004. 10.1136/bmjgh-2021-007004</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-007004</ArticleId><ArticleId IdType="pmc">PMC8460526</ArticleId><ArticleId IdType="pubmed">34551971</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman BP, Khoury JA, Blair JE, et al. . COVID-19 Dysautonomia. Front Neurol 2021;12:624968. 10.3389/fneur.2021.624968</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.624968</ArticleId><ArticleId IdType="pmc">PMC8076737</ArticleId><ArticleId IdType="pubmed">33927679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L, O&#x2019;Boyle S, Palla L, et al. . How Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS) progresses: the natural history of ME/CFS. Front Neurol 2020;11:826. 10.3389/fneur.2020.00826</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00826</ArticleId><ArticleId IdType="pmc">PMC7431524</ArticleId><ArticleId IdType="pubmed">32849252</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S, Brenu EW, Staines DR, et al. . The adoption of chronic fatigue syndrome/Myalgic Encephalomyelitis case definitions to assess prevalence: A systematic review. Ann Epidemiol 2013;23:371&#x2013;6. 10.1016/j.annepidem.2013.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2013.04.003</ArticleId><ArticleId IdType="pubmed">23683713</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (U.S.) . Committee on the diagnostic criteria for Myalgic Encephalomyelitis/chronic fatigue syndrome, Institute of medicine (U.S.). board on the health of select populations. beyond Myalgic Encephalomyelitis/chronic fatigue syndrome: redefining an illness.</Citation></Reference><Reference><Citation>Lacerda EM, Geraghty K, Kingdon CC, et al. . A logistic regression analysis of risk factors in ME/CFS pathogenesis. BMC Neurol 2019;19:275. 10.1186/s12883-019-1468-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-019-1468-2</ArticleId><ArticleId IdType="pmc">PMC6839177</ArticleId><ArticleId IdType="pubmed">31699051</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R, Riste L, Hann M, et al. . Into the looking glass: post-viral syndrome post COVID-19. Medical Hypotheses 2020;144:110055. 10.1016/j.mehy.2020.110055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110055</ArticleId><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons D, Frampton M, Naqvi S, et al. . Fallout from the COVID-19 pandemic-should we prepare for a tsunami of post viral depression Ir J Psychol Med 2020;37:295&#x2013;300. 10.1017/ipm.2020.40</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ipm.2020.40</ArticleId><ArticleId IdType="pmc">PMC7431842</ArticleId><ArticleId IdType="pubmed">32408926</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos MC, Nery T, Starke AC, et al. . Post-viral fatigue in COVID-19: A review of symptom assessment methods, mental, cognitive, and physical impairment. Neurosci Biobehav Rev 2022;142:104902. 10.1016/j.neubiorev.2022.104902</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2022.104902</ArticleId><ArticleId IdType="pmc">PMC9528075</ArticleId><ArticleId IdType="pubmed">36202253</ArticleId></ArticleIdList></Reference><Reference><Citation>Legler AF, Meyer-Arndt L, M&#xf6;dl L, et al. . Symptom persistence and biomarkers in post-COVID-19/chronic fatigue syndrome &#x2013; results from a prospective observational cohort. Neurology [Preprint] 2023. 10.1101/2023.04.15.23288582</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.15.23288582</ArticleId><ArticleId IdType="pmc">PMC10469383</ArticleId><ArticleId IdType="pubmed">37662515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Tian L, Marconi VC, et al. . Low-dose Naltrexone use for the management of post-acute sequelae of COVID-19. International Immunopharmacology 2023;124:110966. 10.1016/j.intimp.2023.110966</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110966</ArticleId><ArticleId IdType="pmc">PMC11028858</ArticleId><ArticleId IdType="pubmed">37804660</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, et al. . Safety and efficacy of low dose Naltrexone in a long Covid cohort; an Interventional pre-post study. Brain Behav Immun Health 2022;24:100485. 10.1016/j.bbih.2022.100485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava AB, Gold MS. Naltrexone: A history and future directions. Cerebrum 2018;2018:cer-13-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6353110</ArticleId><ArticleId IdType="pubmed">30746025</ArticleId></ArticleIdList></Reference><Reference><Citation>Product monograph: Apo-Naltrexone. Toronto, 2015.</Citation></Reference><Reference><Citation>Toljan K, Vrooman B. Low-dose Naltrexone (LDN)-Review of therapeutic utilization. Medical Sciences 2018;6:82. 10.3390/medsci6040082</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6040082</ArticleId><ArticleId IdType="pmc">PMC6313374</ArticleId><ArticleId IdType="pubmed">30248938</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker CE, Nguyen TM, Segal D, et al. . Low dose Naltrexone for induction of remission in Crohn&#x2019;s disease. Cochrane Database Syst Rev 2018;4:CD010410. 10.1002/14651858.CD010410.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD010410.pub3</ArticleId><ArticleId IdType="pmc">PMC6494424</ArticleId><ArticleId IdType="pubmed">29607497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton MJ, Chapman BP, Van Marwijk H. Low-dose Naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep 2020;13:e232502. 10.1136/bcr-2019-232502</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232502</ArticleId><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O, Pesonen P, Tuominen E. Low-dose Naltrexone in the treatment of Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health &amp; Behavior 2019;7:207&#x2013;17. 10.1080/21641846.2019.1692770</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose Naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010;68:145&#x2013;50. 10.1002/ana.22006</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22006</ArticleId><ArticleId IdType="pubmed">20695007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatfield E, Phillips K, Swidan S, et al. . Use of low-dose Naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc 2020;151:891&#x2013;902. 10.1016/j.adaj.2020.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.adaj.2020.08.019</ArticleId><ArticleId IdType="pubmed">33228882</ArticleId></ArticleIdList></Reference><Reference><Citation>Aitcheson N, Lin Z, Tynan K. Focus | research low-dose Naltrexone in the treatment of Fibromyalgia A systematic review and narrative synthesis. Aust J Gen Pract 2023;52:189&#x2013;95. 10.31128/AJGP-09-22-6564</Citation><ArticleIdList><ArticleId IdType="doi">10.31128/AJGP-09-22-6564</ArticleId><ArticleId IdType="pubmed">37021443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun KD, Amris K, Vaegter HB, et al. . Low-dose Naltrexone for the treatment of Fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials 2021;22:804. 10.1186/s13063-021-05776-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05776-7</ArticleId><ArticleId IdType="pmc">PMC8591911</ArticleId><ArticleId IdType="pubmed">34781989</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger J, Noor N, McCue R, et al. . Low-dose Naltrexone for the treatment of Fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 2013;65:529&#x2013;38. 10.1002/art.37734</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37734</ArticleId><ArticleId IdType="pubmed">23359310</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose Naltrexone in the management of chronic pain and inflammation in multiple sclerosis, Fibromyalgia, Crohn&#x2019;s disease, and other chronic pain disorders. Pharmacotherapy 2018;38:382&#x2013;9. 10.1002/phar.2086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2086</ArticleId><ArticleId IdType="pubmed">29377216</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver CN, D&#x2019;Souza RS. Efficacy of low-dose Naltrexone and predictors of treatment success or discontinuation in Fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise-wide retrospective analysis. Biomedicines 2023;11:1087. 10.3390/biomedicines11041087</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11041087</ArticleId><ArticleId IdType="pmc">PMC10135963</ArticleId><ArticleId IdType="pubmed">37189705</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomer-Carbonell A, Sanabria-Mazo JP, Hern&#xe1;ndez-Negr&#xed;n H, et al. . Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and Neurobiological effects of low-dose Naltrexone (LDN) in patients with Fibromyalgia (INNOVA study). BMJ Open 2022;12:e055351. 10.1136/bmjopen-2021-055351</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-055351</ArticleId><ArticleId IdType="pmc">PMC8739052</ArticleId><ArticleId IdType="pubmed">34992118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekelem C, Juhasz M, Khera P, et al. . Utility of Naltrexone treatment for chronic inflammatory Dermatologic conditions: A systematic review. JAMA Dermatol 2019;155:229&#x2013;36. 10.1001/jamadermatol.2018.4093</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2018.4093</ArticleId><ArticleId IdType="pubmed">30484835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mischoulon D, Hylek L, Yeung AS, et al. . Randomized, proof-of-concept trial of low dose Naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord 2017;208:6&#x2013;14. 10.1016/j.jad.2016.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.08.029</ArticleId><ArticleId IdType="pubmed">27736689</ArticleId></ArticleIdList></Reference><Reference><Citation>Due Bruun K, Christensen R, Amris K, et al. . Naltrexone 6 mg once daily versus placebo in women with Fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol 2024;6:e31&#x2013;9. 10.1016/S2665-9913(23)00278-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(23)00278-3</ArticleId><ArticleId IdType="pubmed">38258677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R, Kareem ZY, McLaughlin PJ. Acute low dose Naltrexone increases &#x392;-Endorphin and promotes neuronal recovery following hypoxia-ischemic stroke in Type-2 diabetic mice. Neurochem Res 2023;48:2835&#x2013;46. 10.1007/s11064-023-03938-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-023-03938-4</ArticleId><ArticleId IdType="pubmed">37166576</ArticleId></ArticleIdList></Reference><Reference><Citation>Panerai AE, Vecchiet J, Panzeri P, et al. . Panerai Chronjourpain 2001 peripheral blood mononuclear cell &#x392;-Endorphin concentration is decreased in chronic fatigue syndrome and Fibromyalgia but not in depression_ preliminary report. The Clinical Journal of Pain 2002;18:270&#x2013;3. 10.1097/00002508-200207000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002508-200207000-00008</ArticleId><ArticleId IdType="pubmed">12131069</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNF&#x3b1; production in human immune cell Subsets following stimulation with ligands for intracellular toll-like receptors. Front Immunol 2017;8:809. 10.3389/fimmu.2017.00809</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00809</ArticleId><ArticleId IdType="pmc">PMC5504148</ArticleId><ArticleId IdType="pubmed">28744288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson MR, Zhang Y, Brown K, et al. . Non-stereoselective reversal of neuropathic pain by naloxone and Naltrexone: involvement of toll-like receptor 4 (Tlr4). Eur J Neurosci 2008;28:20&#x2013;9. 10.1111/j.1460-9568.2008.06321.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06321.x</ArticleId><ArticleId IdType="pmc">PMC2588470</ArticleId><ArticleId IdType="pubmed">18662331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku&#x10d;i&#x107; N, Ra&#x10d;ki V, &#x160;verko R, et al. . Immunometabolic Modulatory role of Naltrexone in Bv&#x2010;2 Microglia cells. IJMS 2021;22:8429. 10.3390/ijms22168429</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168429</ArticleId><ArticleId IdType="pmc">PMC8395119</ArticleId><ArticleId IdType="pubmed">34445130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwilasz AJ, Todd LS, Duran-Malle JC, et al. . Experimental autoimmune encephalopathy (EAE)-Induced hippocampal Neuroinflammation and memory deficits are prevented with the non-opioid Tlr2/Tlr4 antagonist (+)-Naltrexone. Behav Brain Res 2021;396:112896. 10.1016/j.bbr.2020.112896</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2020.112896</ArticleId><ArticleId IdType="pmc">PMC7572683</ArticleId><ArticleId IdType="pubmed">32905811</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. . The IL-1&#x392;, IL-6, and TNF cytokine Triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022;3:100663. 10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga J, Lepra M, Kish SJ, et al. . Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry 2023;80:787&#x2013;95. 10.1001/jamapsychiatry.2023.1321</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2023.1321</ArticleId><ArticleId IdType="pmc">PMC10233457</ArticleId><ArticleId IdType="pubmed">37256580</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, et al. . Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 2022;185:2452&#x2013;68. 10.1016/j.cell.2022.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson T, Zhang L-X, Guo H, et al. . Brainstem abnormalities in Myalgic Encephalomyelitis/chronic fatigue syndrome: A Scoping review and evaluation of magnetic resonance imaging findings. Front Neurol 2021;12:769511. 10.3389/fneur.2021.769511</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.769511</ArticleId><ArticleId IdType="pmc">PMC8718708</ArticleId><ArticleId IdType="pubmed">34975729</ArticleId></ArticleIdList></Reference><Reference><Citation>Renz-Polster H, Tremblay M-E, Bienzle D, et al. . The Pathobiology of Myalgic Encephalomyelitis/chronic fatigue syndrome: the case for Neuroglial failure. Front Cell Neurosci 2022;16:888232. 10.3389/fncel.2022.888232</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.888232</ArticleId><ArticleId IdType="pmc">PMC9124899</ArticleId><ArticleId IdType="pubmed">35614970</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fairbank R. An overdose drug shows promise for long COVID patients. Natl Geogr Mag; 2023. Available: https://www.nationalgeographic.com/premium/article/drug-overdose-low-dose-naltrexone-long-covid [Accessed 9 Jul 2023].</Citation></Reference><Reference><Citation>
Yuko E. Can an addiction drug treat long Covid? rolling stone. 2023. Available: https://www.rollingstone.com/culture/culture-features/long-covid-treatment-addiction-drug-1234701573/ [Accessed 8 Jul 2023].</Citation></Reference><Reference><Citation>
Steenhuysen J. Addiction drug shows promise lifting long COVID brain fog, fatigue Reuters. 2022. Available: https://www.reuters.com/business/healthcare-pharmaceuticals/addiction-drug-shows-promise-lifting-long-covid-brain-fog-fatigue-2022-10-18/ [Accessed 8 Jul 2023].</Citation></Reference><Reference><Citation>
Velasquez-Manoff M. What if you never get better from COVID-19?
N Y Times Mag; 2021. Available: https://www.nytimes.com/2021/01/21/magazine/covid-aftereffects.html
</Citation></Reference><Reference><Citation>Ducharme J. Researchers are getting closer to learning how to treat and prevent long COVID time. 2023.</Citation></Reference><Reference><Citation>
Castro-Root G. Game Changer&#x2019;: 5 long COVID treatments researchers are most excited about. San Francisco Chronicle; 2023. Available: https://www.sfchronicle.com/health/article/long-covid-treatment-18144379.php [Accessed 8 Jul 2023].</Citation></Reference><Reference><Citation>
Graedon J. Should Doctors Consider Low Dose Naltrexone for Long COVID? The People&#x2019;s Pharmacy, 2023. Available: https://www.peoplespharmacy.com/articles/should-doctors-consider-low-dose-naltrexone-for-long-covid [Accessed 8 Jul 2023].</Citation></Reference><Reference><Citation>Brown S. Low-dose Naltrexone could treat long COVID symptoms. Verywellhealth 2023;6. 10.3390/medsci6040082</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6040082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Tian L, Marconi VC, et al. . Low-dose Naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol 2023;124:110966. 10.1016/j.intimp.2023.110966</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110966</ArticleId><ArticleId IdType="pmc">PMC11028858</ArticleId><ArticleId IdType="pubmed">37804660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A-W, Tetzlaff JM, G&#xf8;tzsche PC, et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A, Malbeuf M, Hoens AM, et al. . Creating a provincial post COVID-19 Interdisciplinary clinical care network as a learning health system during the pandemic: integrating clinical care and research. Learn Health Syst 2022;7:e10316. 10.1002/lrh2.10316</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lrh2.10316</ArticleId><ArticleId IdType="pmc">PMC9348470</ArticleId><ArticleId IdType="pubmed">35942206</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik H, Malbeuf M, Shao S, et al. . A learning health system for long Covid care and research in British Columbia. NEJM Catalyst 2023;4. 10.1056/CAT.23.0120</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/CAT.23.0120</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik H, Malbeuf M, Levin A. Expanding the learning health care system beyond the academic health center. Acad Med 2023;98:973. 10.1097/ACM.0000000000005273</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACM.0000000000005273</ArticleId><ArticleId IdType="pubmed">37797301</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik H, Li R, Shao S, et al. . D-Dimer elevation and venous thromboembolism &#x2265;90 days following COVID-19. Can Journ Gen Int Med 2023;18:43&#x2013;8. 10.22374/cjgim.v18i2.688</Citation><ArticleIdList><ArticleId IdType="doi">10.22374/cjgim.v18i2.688</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulter T, Prestley N, Lai S, et al. . Characterizing the complex chronic diseases program&#x2019;s (CCDP) patient population presenting for management of Fibromyalgia, Myalgic Encephalomyelitis, and symptoms attributed to chronic Lyme disease at BC women&#x2019;s hospital + health centre. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Conference; 2021.</Citation></Reference><Reference><Citation>MEDISCA . Certificate of analysis Naltrexone hydrochloride, USP*. 2021.</Citation></Reference><Reference><Citation>MEDISCA . CERTIFICATE OF ANALYSIS CELLULOSE, NF/EP (Microcrystalline)(Flocel&#xae; 101). 2021.</Citation></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir-Nash J, et al. . The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121&#x2013;3. 10.1001/archneur.1989.00520460115022</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdal A. Fatigue Severity Scale. Encyclopedia of Quality of Life and Well-Being Research. Springer International Publishing, 2022:1&#x2013;5.Available: 10.1007/978-3-319-69909-7_1018-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-69909-7_1018-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuberger GB. Measures of fatigue: the fatigue questionnaire, fatigue severity scale, multidimensional assessment of fatigue scale, and short Form-36 vitality (energy/fatigue) Subscale of the short form health survey. Arthritis &amp; Rheumatism 2003;49:S175&#x2013;83. 10.1002/art.11405</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11405</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassini V, Pozzilli C, Onesti E, et al. . Comparison of the effects of acetyl L-Carnitine and Amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004;218:103&#x2013;8. 10.1016/j.jns.2003.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2003.11.005</ArticleId><ArticleId IdType="pubmed">14759641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried MW, Buti M, Dore GJ, et al. . Once-daily Simeprevir (Tmc435) with pegylated interferon and ribavirin in treatment-Na&#xef;ve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918&#x2013;29. 10.1002/hep.26641</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26641</ArticleId><ArticleId IdType="pmc">PMC4112500</ArticleId><ArticleId IdType="pubmed">23907700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D-Y, Lee J-S, Park S-Y, et al. . Systematic review of randomized controlled trials for chronic fatigue syndrome/Myalgic Encephalomyelitis (CFS/ME). J Transl Med 2020;18. 10.1186/s12967-019-02196-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02196-9</ArticleId><ArticleId IdType="pmc">PMC6943902</ArticleId><ArticleId IdType="pubmed">31906979</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, et al. . Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil 2022;101:48&#x2013;52. 10.1097/PHM.0000000000001910</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Cassar MP, Tunnicliffe EM, et al. . Medium-term effects of SARS-Cov-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021;31:100683. 10.1016/j.eclinm.2020.100683</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>
Cella D, Dimmock M, Friedberg F, et al. . NINDS CDE project Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue Subgroup; 2017. Available: https://www.commondataelements.ninds.nih.gov/sites/nindscde/files/Doc/MECFS/Fatigue_Subgroup_Summary.pdf [Accessed 20 Nov 2023].</Citation></Reference><Reference><Citation>Gorst SL, Seylanova N, Dodd SR, et al. . Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study. Lancet Respir Med 2023;11:1101&#x2013;14. 10.1016/S2213-2600(23)00370-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00370-3</ArticleId><ArticleId IdType="pubmed">37926103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawker GA, Mian S, Kendzerska T, et al. . Measures of adult pain: visual analog scale for pain (VAS pain), Numeric rating scale for pain (NRS pain) McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S240&#x2013;52. 10.1002/acr.20543</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20543</ArticleId><ArticleId IdType="pubmed">22588748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L, Authier FJ, Scheibenbogen C, et al. . European network on Myalgic Encephalomyelitis/chronic fatigue syndrome (EUROMENE): expert consensus on the diagnosis, service provision, and care of people with me/CFS in Europe. Medicina (Kaunas) 2021;57:510. 10.3390/medicina57050510</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050510</ArticleId><ArticleId IdType="pmc">PMC8161074</ArticleId><ArticleId IdType="pubmed">34069603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacerda EM, Mudie K, Kingdon CC, et al. . The UK ME/CFS Biobank: A disease-specific Biobank for advancing clinical research into Myalgic Encephalomyelitis/chronic fatigue syndrome. Front Neurol 2018;9:1026. 10.3389/fneur.2018.01026</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01026</ArticleId><ArticleId IdType="pmc">PMC6288193</ArticleId><ArticleId IdType="pubmed">30564186</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie F, Pullenayegum E, Gaebel K, et al. . A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care 2016;54:98&#x2013;105. 10.1097/MLR.0000000000000447</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000447</ArticleId><ArticleId IdType="pmc">PMC4674140</ArticleId><ArticleId IdType="pubmed">26492214</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris T, Kerry SM, Limb ES, et al. . Physical activity levels in adults and older adults 3&#x2013;4 years after Pedometer-based walking interventions: long-term follow-up of participants from two randomised controlled trials in UK primary care. PLoS Med 2018;15:e1002526. 10.1371/journal.pmed.1002526</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002526</ArticleId><ArticleId IdType="pmc">PMC5844512</ArticleId><ArticleId IdType="pubmed">29522529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan CM, Maddocks M, Canavan JL, et al. . Pedometer step count targets during pulmonary rehabilitation in chronic obstructive pulmonary disease: A randomized controlled trial. Am J Respir Crit Care Med 2017;195:1344&#x2013;52. 10.1164/rccm.201607-1372OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201607-1372OC</ArticleId><ArticleId IdType="pmc">PMC5443901</ArticleId><ArticleId IdType="pubmed">27911566</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcherbina A, Hershman SG, Lazzeroni L, et al. . The effect of Digital physical activity interventions on daily step count: a randomised controlled crossover Substudy of the Myheart counts cardiovascular health study. Lancet Digit Health 2019;1:e344&#x2013;52. 10.1016/S2589-7500(19)30129-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(19)30129-3</ArticleId><ArticleId IdType="pubmed">33323209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H. Minimum important difference is minimally important in sample size calculations. Trials 2023;24:34. 10.1186/s13063-023-07092-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-023-07092-8</ArticleId><ArticleId IdType="pmc">PMC9847050</ArticleId><ArticleId IdType="pubmed">36650587</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin &#xc5;, Taft C, Lundgren-Nilsson &#xc5;, et al. . Minimal important differences for fatigue patient reported outcome measures - A systematic review. BMC Med Res Methodol 2016;16. 10.1186/s12874-016-0167-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0167-6</ArticleId><ArticleId IdType="pmc">PMC4937582</ArticleId><ArticleId IdType="pubmed">27387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher EC, Pouchot J, Brant R, et al. . Minimal clinically important difference f or 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 2008;35:635&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322987</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, et al. . The Redcap consortium: building an international community of software platform partners. Journal of Biomedical Informatics 2019;95:103208. 10.1016/j.jbi.2019.103208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (Redcap)-A Metadata-driven methodology and Workflow process for providing Translational research Informatics support. Journal of Biomedical Informatics 2009;42:377&#x2013;81. 10.1016/j.jbi.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med 2017;377:1391&#x2013;8. 10.1056/NEJMsm1605385</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsm1605385</ArticleId><ArticleId IdType="pubmed">28976864</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Hopewell S, Schulz KF, et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. 10.1136/bmj.c869</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c869</ArticleId><ArticleId IdType="pmc">PMC2844943</ArticleId><ArticleId IdType="pubmed">20332511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Hassler A, Bostr&#xf6;m E, et al. . Hyperbaric oxygen therapy for long COVID (HOT-Loco), an interim safety report from a randomised controlled trial. BMC Infect Dis 2023;23:33. 10.1186/s12879-023-08002-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08002-8</ArticleId><ArticleId IdType="pmc">PMC9854077</ArticleId><ArticleId IdType="pubmed">36670365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Abdel-Halim L, Hassler A, et al. . Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-Loco): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open 2022;12:e061870. 10.1136/bmjopen-2022-061870</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061870</ArticleId><ArticleId IdType="pmc">PMC9638753</ArticleId><ArticleId IdType="pubmed">36323462</ArticleId></ArticleIdList></Reference><Reference><Citation>Badran BW, Huffman SM, Dancy M, et al. . A pilot randomized controlled trial of supervised, at-home, self-administered Transcutaneous Auricular Vagus nerve stimulation (taVNS) to manage long COVID symptoms. Bioelectron Med 2022;8:13. 10.1186/s42234-022-00094-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42234-022-00094-y</ArticleId><ArticleId IdType="pmc">PMC9402278</ArticleId><ArticleId IdType="pubmed">36002874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, et al. . Hyperbaric oxygen therapy improves Neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep 2022;12:11252. 10.1038/s41598-022-15565-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15565-0</ArticleId><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, et al. . Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond) 2021;21:e629&#x2013;32. 10.7861/clinmed.2021-0462</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId><ArticleId IdType="pmc">PMC8806311</ArticleId><ArticleId IdType="pubmed">34862223</ArticleId></ArticleIdList></Reference><Reference><Citation>
Singh U, Geng L. Paxlovid for Treatment of Long Covid (STOP-PASC), 2022. Available: https://classic.clinicaltrials.gov/ct2/show/NCT05576662 [Accessed 9 2023].</Citation></Reference><Reference><Citation>Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of long COVID: A case series. J Neuroimmunol 2022;362:577784. 10.1016/j.jneuroim.2021.577784</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577784</ArticleId><ArticleId IdType="pmc">PMC8653406</ArticleId><ArticleId IdType="pubmed">34922127</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernon SD, Hartle M, Sullivan K, et al. . Post-Exertional malaise among people with long COVID compared to Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Work 2023;74:1179&#x2013;86. 10.3233/WOR-220581</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/WOR-220581</ArticleId><ArticleId IdType="pubmed">36911963</ArticleId></ArticleIdList></Reference><Reference><Citation>Damant RW, Rourke L, Cui Y, et al. . Reliability and validity of the post COVID-19 condition stigma questionnaire: A prospective cohort study. EClinicalMedicine 2023;55:101755. 10.1016/j.eclinm.2022.101755</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101755</ArticleId><ArticleId IdType="pmc">PMC9694932</ArticleId><ArticleId IdType="pubmed">36447641</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lowenstein F, Vazquez A. Open letter to the NIH. Body Politic; 2023. Available: https://www.wearebodypolitic.com/bodytype/2021/4/22/open-letter-to-nih [Accessed 8 Jul 2023].</Citation></Reference><Reference><Citation>
Cohrs R. A slow-moving Glacier&#x2019;: NIH&#x2019;s sluggish and often opaque efforts to study long Covid draw patient, expert ire. STAT News; 2022. Available: https://www.statnews.com/2022/03/29/nih-long-covid-sluggish-study/ [Accessed 27 Dec 2023].</Citation></Reference><Reference><Citation>
Cohrs R, Ladyzhets B. The NIH has poured $1 billion into long Covid research-with little to show for it. STAT News
2023. Available: https://www.statnews.com/2023/04/20/long-covid-nih-billion/
</Citation></Reference><Reference><Citation>Rubin R. As their numbers grow, COVID-19 &#x2018;long haulers&#x2019; stump experts. JAMA 2020;324:1381. 10.1001/jama.2020.17709</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17709</ArticleId><ArticleId IdType="pubmed">32965460</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, et al. . Unexplained post-acute infection syndromes. Nat Med 2022;28:911&#x2013;23. 10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L, de Barros B, Kingdon CC, et al. . Evidence of clinical pathology abnormalities in people with Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS) from an analytic cross-sectional study. Diagnostics (Basel) 2019;9:41. 10.3390/diagnostics9020041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9020041</ArticleId><ArticleId IdType="pmc">PMC6627354</ArticleId><ArticleId IdType="pubmed">30974900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-N&#xfa;&#xf1;ez B, Tarasse R, Vogelaar EF, et al. . Higher prevalence of &#x2018;low T3 syndrome&#x2019; in patients with chronic fatigue syndrome: A case-control study. Front Endocrinol (Lausanne) 2018;9:97. 10.3389/fendo.2018.00097</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00097</ArticleId><ArticleId IdType="pmc">PMC5869352</ArticleId><ArticleId IdType="pubmed">29615976</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul LC, Mudie K, Kingdon CC, et al. . Hand grip strength as a clinical biomarker for ME/CFS and disease severity. Front Neurol 2018;9:992. 10.3389/fneur.2018.00992</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00992</ArticleId><ArticleId IdType="pmc">PMC6277492</ArticleId><ArticleId IdType="pubmed">30538664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>